AUTL Autolus Therapeutics plc
Debt Financing ·
Autolus issued an initial $75 million of notes to Perceptive Advisors on July 30, 2026 under a five-year, interest-only credit facility of up to $250 million. The company's outlook for cash into the second quarter of 2028 counts the first two tranches totaling $100 million.
The senior secured notes mature July 30, 2031. Perceptive also received a warrant for up to 3,500,000 American Depositary Shares at $1.9314 each.
Autolus will cut about 13% of its workforce and expects about $8 million in severance and related charges, with savings of about $15 million a year from 2027. It reiterated 2026 AUCATZYL revenue guidance of $120 million to $135 million, while its 10-K reports a 2025 net loss of $287.5 million and cash used in operations of $283.6 million.
The company expects about $8 million in restructuring charges and continues to expect its cash to fund operations into the fourth quarter of 2027.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $10.1 million | |
| Research and development | $117.7 million | $138.4 million |
| Net income (loss) | -$287.5 million | -$220.7 million |
| Cash from operations | -$283.6 million | -$206.3 million |
| Cash and equivalents | $104.1 million | $227.4 million |
| Short-term investments | $196.6 million | $360.6 million |
Our latest story on this, dated Apr 29, 2026: "Autolus Therapeutics cuts about 13% of staff, targets $15 million in annual savings". The story links the filing or release it is based on. Read the story.
Autolus Therapeutics plc trades under the ticker AUTL on NASDAQ.
Autolus Therapeutics plc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Autolus Therapeutics plc is 1730463. Its filings are on SEC EDGAR.
266,162,540 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Autolus Therapeutics plc under United Kingdom.
Our directory classifies Autolus Therapeutics plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Autolus Therapeutics plc is US05280R1005.
aibio.space lists Autolus Therapeutics plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as X0.
Autolus Therapeutics plc reported a net loss of $287.5 million for the fiscal year ended Dec 31, 2025, and used $283.6 million of cash in operations, per its annual report to the SEC.
$117.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$201.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Autolus Therapeutics, dated Aug 3, 2026: "Autolus issues first $75 million under up to $250 million Perceptive facility". Autolus issued an initial $75 million of notes to Perceptive Advisors on July 30, 2026 under a five-year, interest-only credit facility of up to $250 million. The company's outlook for cash into the second quarter of 2028 counts the first two tranches totaling $100 million. Source.
Our latest financing story, dated Aug 3, 2026: "Autolus issues $75.0 million of notes under up to $250.0 million Perceptive facility". The senior secured notes mature July 30, 2031. Perceptive also received a warrant for up to 3,500,000 American Depositary Shares at $1.9314 each. Source.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 5.02,7.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio